Altos Labs and the $3 Billion Bet on Reversing Cellular Aging

Altos Labs is a biotechnology company that launched in January 2022 with what was reported to be around $3 billion in initial financing, a sum that made it, by most accounts, the best-funded startup debut in the history of the industry. Its stated goal is to understand and reverse the process of cellular aging, and it is pursuing that goal through a technology called cellular reprogramming. According to reporting by MIT Technology Review, the company assembled a roster of senior scientists at salaries reported to reach $1 million or more a year, drawing researchers away from prestigious academic posts.

The company matters because of who is behind it, how much money it commands, and the specific scientific idea it is built on. That idea, partial reprogramming, has produced some of the most striking results in aging biology over the past decade. It has also produced clear warning signs. The honest summary is that the approach is promising in animals and almost entirely unproven in people.

Who built Altos Labs and who funded it

Altos was co-founded and led by Richard Klausner, a former director of the U.S. National Cancer Institute, alongside biotech executive Hans Bishop. The company incorporated in both the United States and the United Kingdom and built research sites in the San Francisco Bay Area, San Diego and Cambridge, England.

The backers reported in coverage by CBS News and Scientific American include Amazon founder Jeff Bezos and investor Yuri Milner, along with the venture firm ARCH Venture Partners. The precise size of individual stakes has not been fully disclosed, and the often-quoted $3 billion figure comes from reporting rather than a detailed public filing, so it is best treated as a reported estimate. This places Altos in the same wave of large private money flowing into longevity science. For more on that trend, see our coverage of Sam Altman and Retro Biosciences.

The all-star science team

What set Altos apart was not only the money but the names. Shinya Yamanaka, who won the 2012 Nobel Prize in Physiology or Medicine for showing that adult cells can be reset into a stem-cell-like state, serves as a senior scientific advisor. Altos has said he works in that role without pay and oversees research in Japan.

The company also recruited Juan Carlos Izpisua Belmonte, the Salk Institute biologist whose lab produced landmark partial-reprogramming experiments, and Steve Horvath, the developer of the widely used epigenetic “clock” that estimates biological age from chemical marks on DNA. Horvath’s tools are central to the broader debate covered in our piece on epigenetic clocks and biological age testing. Other recruits named in press reports include reprogramming specialist Wolf Reik and cell biologist Peter Walter.

What partial reprogramming actually is

To understand the bet, start with Yamanaka’s discovery. In 2006 he identified four genes, often abbreviated OSKM after the proteins Oct4, Sox2, Klf4 and c-Myc, that together can turn an ordinary adult cell back into an induced pluripotent stem cell. A pluripotent cell is a blank slate that can become almost any tissue. As part of that process, the cell appears to shed many of the molecular marks of age.

Full reprogramming is not what longevity researchers want. A cell reset all the way to a stem state forgets its job, and a skin cell that no longer behaves like a skin cell is useless or dangerous. Partial reprogramming is the attempt to switch the Yamanaka factors on briefly, then off again, so the cell sheds signs of aging while keeping its original identity. The aim is to rejuvenate, not to erase.

What the lab data has shown, and what it has not

The proof of concept that energized the field came from Izpisua Belmonte’s group. In a 2016 paper in the journal Cell, “In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming”, the team engineered mice to express the four factors and switched them on in short pulses. In a mouse model of progeria, a premature-aging condition, the brief cyclic treatment extended lifespan by roughly a third compared with untreated animals, and in normal old mice it improved healing of muscle and pancreatic tissue. The Salk Institute described the work as turning back signs of aging.

Other groups have added to the picture. A 2020 Harvard-led study reported that delivering three of the factors restored vision in aged and injured mouse eyes. Later work, including a study in Nature’s Communications Biology, found that cyclic rather than continuous expression of the factors improved memory-related measures in aged mice.

Two cautions run through all of this. First, these are animal results, mostly in mice, and mouse aging is not human aging. Second, the same Cell paper that excited the field also showed the danger: when the factors were left on continuously, the mice died within days from organ failure. As MIT Technology Review reported, some reprogramming experiments produced teratomas, the embryonic-type tumors that form when cells are pushed too far toward the stem state.

The safety question and the road to the clinic

Cancer risk is the central obstacle, not a footnote. Pushing a cell toward pluripotency is, by definition, pushing it toward uncontrolled growth, which is why many researchers drop c-Myc, the factor most associated with cancer, and why dosing and timing are treated as life-or-death variables. Scientists quoted by Scientific American have stressed that getting the balance wrong could leave cells unable to function or could turn them cancerous.

For now, in-vivo reprogramming remains largely pre-clinical. Altos has framed its early work as basic science aimed at understanding cell rejuvenation rather than a near-term product. A separate company, Life Biosciences, has reported plans for an early human trial using three Yamanaka factors delivered to the eye in a small group of glaucoma patients, a study designed mainly to test safety. That distinction matters: a first-in-human safety trial is a long way from proof that reprogramming reverses aging or treats disease in people.

The broader contrast is with longevity approaches already in or near human testing, such as the repurposed drugs covered in our report on rapamycin, metformin and senolytics. Reprogramming aims higher, at the cell’s aging program itself, but it also sits further from clinical proof.

FAQ

Has Altos Labs reversed aging in humans? No. There is no published evidence that Altos has reversed aging in people. The encouraging results so far come from animal studies, mainly mice, and the company has described its early effort as foundational research rather than an available therapy.

Is cellular reprogramming safe? It is not yet established as safe in humans. The main concern is cancer, because the reprogramming process moves cells toward an uncontrolled, stem-like state. Researchers try to manage this with partial, short-pulse dosing, but the safety margin in people is still being studied.

Who funds Altos Labs? Backers reported in the press include Jeff Bezos, investor Yuri Milner and ARCH Venture Partners. The widely cited launch figure of about $3 billion comes from media reporting rather than a detailed public disclosure.

Sources

1. MIT Technology Review — Meet Altos Labs, Silicon Valley’s latest wild bet on living forever
2. CBS News — Jeff Bezos reportedly invests in Altos Labs
3. Scientific American — Billionaires Bankroll Cell Rejuvenation Tech
4. Cell — In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming (2016)
5. Salk Institute — Turning back time: Salk scientists reverse signs of aging
6. Nature Communications Biology — Cyclic overexpression of Yamanaka factors in neurons
7. Scientific American — This method to reverse cellular aging is about to be tested in humans